Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BreathScan Alcohol Detection - Product Extension

9 Jun 2010 07:00

RNS Number : 2718N
Akers Biosciences, Inc.
09 June 2010
 

Embargoed: 0700hrs, 9 June 2010

 

 

Akers Biosciences, Inc.

("ABI" or the "Company")

 

ABI Releases BreathScan PRO to Merge Disposable Convenience and Quantitative Precision

 

Akers Biosciences, Inc (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, today announces the initiation of production of a BreathScan alcohol detection product line extension designed for forensic use by trained professionals in law enforcement and other applicable markets, merging the convenience of the Company's proprietary breath alcohol detection technology with the quantitative precision of an electronic analyzer. The System will be branded under the trade name BreathScan PRO and will allow users to determine a subject's breath alcohol level within the range of 0.00% to 0.15%. A test result that is calculated above that range will display on the analyzer's digital read-out as ">0.15%".

The BreathScan PRO system will utilize a specially formulated disposable alcohol detector to collect a breath sample from each test subject. The used detector is then inserted into the BreathScan PRO digital analyzer to obtain a quantitative breath alcohol level for each individual.

Initially, the system will be marketed worldwide for forensic use by trained professionals, including those in civil and military law enforcement, human resources, educational supervision and other safety-related occupations. Some of the scenarios for product use within the "forensic" marketplace will include the following:

·; breath alcohol screenings that seek to quickly and safely establish probable cause for further sobriety or evidential testing by police officers;

·; the assessment of compliance with alcohol safety initiatives related to correctional facilities, work-release programs, employee testing, and school-related events.

User studies are underway to support the Company's application for 510(k) clearance by the US Food and Drug Administration. ABI will seek an Over-the-Counter designation which would further expand the user base of the product in the United States.

ABI will be opening pre-sale of the BreathScan PRO system to its existing distribution network immediately and anticipate that the delivery of the product will commence in September 2010. Product launch to new distributors worldwide will begin early Q4 2010.

Some of the functional highlights of the BreathScan PRO system include the following:

 

·; The one-to-one ratio between breath alcohol detector and breath sample translates into a number of advantages. For one, using the portable BreathScan PRO detectors, several professionals can obtain breath alcohol samples from many test subjects at multiple points of entry/exit. The detectors can then be interpreted by the digital analyzer from within 2 minutes to as long as one hour after the breath sample is obtained. In addition, there is no threat of cross contamination that may exist with other electronic screening devices; those units require numerous persons to provide a breath sample directly into one electronic analyzer.

·; The BreathScan PRO digital analyzer is factory calibrated and never requires recalibration unlike existing screening devices. As a result, organizations that adopt the BreathScan PRO system do not have to factor in system down-time or added expenses related to recalibration activities.

 

·; Unlike most screening devices, BreathScan PRO can be stored and operated at a wide range of temperature conditions(-15C to 50C).

 

Thomas A. Nicolette, President and Chief Executive of ABI, commented,

 

"BreathScan PRO uniquely combines the advantages of one-time use technology with digital sample analysis. The integration of an enduring, electronic reader with custom-calibrated, BreathScan PRO disposable detectors continues our business model focused on recurring revenues. From a competitive standpoint, we are confident that the many advantages of this line extension will be attractive to the global marketplace."

Enquiries:

Thomas A. Nicolette

President and CEO

Tel. +1 856 848 8698

Ben Simons

M: Communications

Tel. +44 (0)20 7920 2340

 

Simon Leathers

Daniel Stewart

Tel. +44 (0)20 7776 6550

 

 

About Akers Biosciences, Inc.

 

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and it products can be found at www.akersbiosciences.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCZVLFBBQFEBBQ
Date   Source Headline
10th Dec 201210:39 amRNSNotice of AGM
26th Nov 20127:00 amRNSDistribution Partnership Forged in China
22nd Oct 20127:00 amRNSIssue of Equity
8th Oct 201212:00 pmRNSHolding(s) in Company
17th Sep 20127:00 amRNSPrivate Placing
17th Sep 20127:00 amRNSHalf Yearly Report
28th Jun 20127:00 amRNSFinal Results
30th Mar 201210:06 amRNSHolding(s) in Company
27th Feb 20125:01 pmRNSDirectorate Change
6th Jan 20127:00 amRNSTrading Update
6th Dec 20117:00 amRNSLaunch of PIFA PLUSS PF4 Rapid Assay
7th Sep 20117:00 amRNSHalf Yearly Report
24th Aug 20117:00 amRNSClinical Trials Commenced: COPD Rapid Assay
30th Jun 20117:00 amRNSUS$3.2 Million Purchase Order for Revelar
10th May 20115:54 pmRNSResult of AGM
28th Apr 20113:41 pmRNSAnnual Report & Accounts & AGM Notice
27th Apr 20117:00 amRNSUS patent protection grant
18th Apr 20117:00 amRNSAsthma Breath Test - Clinical Trials
11th Apr 20117:02 amRNSFinal Results
11th Apr 20117:00 amRNSSupply Agreement & Technology Acquisition
8th Apr 20117:00 amRNSConclusion of HIT Study
16th Mar 20117:00 amRNSPatent Protection - Rapid Blood Cell Separator
2nd Mar 20114:20 pmRNSHolding(s) in Company
28th Feb 20117:00 amRNSTotal Voting Rights
14th Feb 20113:08 pmRNSTR-1 Notification of Major Interest in Shares
14th Feb 20112:57 pmRNSTR-1 Notification of Major Interest in Shares
10th Feb 20117:00 amRNSIssue of Equity & Director Shareholding
1st Feb 20117:00 amRNSPlacing
14th Jan 20117:00 amRNSBreathScan PRO Receives Regulatory Clearance
5th Jan 20117:00 amRNSTrading Statement
29th Dec 20107:00 amRNSOrder for Tri-Cholesterol Tests - Middle East
16th Nov 20101:14 pmRNSIssue of Equity
30th Sep 20103:57 pmRNSHalf Yearly Report
29th Sep 20107:00 amRNSPIFA Heparin/Platelet Factor-4 - New Data
6th Sep 20107:00 amRNSProduct Distribution Expansion: Middle East/India
12th Aug 20107:00 amRNSFurther Distribution Agreement - PIFA Heparin/PF4
21st Jul 20105:18 pmRNSResult of AGM
21st Jun 20107:00 amRNSFinal Results
18th Jun 20107:00 amRNSBreath Ketone Test - Positive Data
14th Jun 20107:00 amRNSUSA Distribution Agreement
9th Jun 20107:00 amRNSBreathScan Alcohol Detection - Product Extension
26th Mar 20104:52 pmRNSHolding(s) in Company
19th Mar 20101:00 pmRNSChange of Adviser
17th Mar 20107:00 amRNSBreathScan Licensing Agreement - UK & Ireland
16th Mar 20107:00 amRNSClinical Study Data - PIFA Heparin
18th Feb 20109:04 amRNSDirector/PDMR Shareholding
30th Dec 20097:00 amRNSDirectorate Change
17th Dec 20099:23 amRNSHolding(s) in Company
15th Dec 20097:00 amRNSABI Obtains GSA Contract
4th Dec 20097:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.